Lunit vs Qure AI (2026)
Two companies that began in chest X-ray and have grown in different directions. Lunit's center of gravity is now breast cancer. INSIGHT MMG and INSIGHT DBT read mammograms and tomosynthesis, and the former Volpara products add density, risk, quality and outreach tools. Its strongest evidence is ScreenTrustCAD, a prospective Swedish screening study of 55,581 women in which AI with one radiologist was noninferior to two radiologists. INSIGHT CXR Triage is its US cleared chest product. Qure has stayed with chest X-ray and head CT and widened its reach, selling in more than 105 countries by its own count, with tuberculosis screening products and care platforms for health programs. Its newest US clearance, qXR-Detect, is a concurrent reading aid for six categories of chest X-ray findings with a Predetermined Change Control Plan. A breast screening program looks at Lunit. A buyer whose need is chest X-ray detection and triage, particularly in tuberculosis screening, looks at Qure.
- Prospective screening evidence: in ScreenTrustCAD (The Lancet Digital Health, 2023), AI with one radiologist was noninferior to two radiologists across 55,581 women.
- A breast cancer platform: detection on mammography and tomosynthesis alongside density, risk, quality and patient outreach products from the former Volpara business.
- Results by patient group: a 2025 preprint led by Emory University with Lunit coauthors reports INSIGHT DBT performance by demographic, imaging and pathology subgroup, lower for noninvasive cancers, calcifications and dense breasts.
- Chest X-ray detection with a cleared change plan: qXR-Detect's Predetermined Change Control Plan, which the company describes as the only one for a chest X-ray detection device.
- Tuberculosis screening evidence from independent studies in several countries and a 2025 systematic review.
- Head CT alongside chest X-ray, with qER cleared for intracranial hemorrhage, mass effect, midline shift and cranial fracture.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Lunit and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Cancer focused medical AI company founded in 2013, headquartered in Seoul and listed on KOSDAQ. Its radiology line is Lunit INSIGHT: MMG for 2D mammography (FDA cleared 2021), DBT for tomosynthesis (cleared 2023) and CXR for chest X-ray (CXR Triage cleared 2021).
Source: AI Health Index, September 2026
Radiology AI company founded in 2016 in Mumbai, with a US entity registered in New York, selling in more than 105 countries through more than 5,500 sites by its own count. Products: qXR for chest X-ray (detection, reporting, lung nodules, tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodule measurement, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, September 2026
Questions buyers ask
How do Lunit and Qure AI work with the EHR?
For Lunit, the company embeds its algorithms directly into imaging hardware through OEM relationships with major scanner manufacturers and distributes via major cloud infrastructure, meaning a customer can acquire the AI as part of equipment already being purchased rather than as a separate integration project.
With Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 25, 2026. No vendor pays for placement.
How are Lunit and Qure AI priced and sold?
Lunit sells INSIGHT and its breast platform direct and through imaging equipment and viewer partners, so the software can arrive inside or alongside a scanner or viewer purchase.
For Qure AI, the portfolio is what makes the silence bite. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 25, 2026. No vendor pays for placement.
How do Lunit and Qure AI handle patient data?
With Lunit, the INSIGHT MMG FAQ says images from commercial sites are retained only for the duration of processing and are not used for retraining, that the models do not learn in real time, and that training data is biopsy proven material sourced through formal collaboration agreements.
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 25, 2026. No vendor pays for placement.
What evidence is published for Lunit and Qure AI?
An independent external evaluation in JAMA Oncology (Salim and colleagues, 2020) compared three commercial algorithms on a retrospective Swedish screening cohort, and Lunit's had the highest accuracy.
Qure's evidence library lists independent diagnostic accuracy studies of qXR for tuberculosis across several countries (the Philippines, Viet Nam, household contacts, a 2025 systematic review and meta-analysis), program evaluations and a cost-effectiveness study in Nigeria, and the company markets its TB products as WHO evaluated. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 25, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Site and publication counts are the companies' own. Lunit's US mammography clearance is for an adjunct viewed after the radiologist's initial read, and using AI in place of a second reader sits outside it. Qure markets sorting out unremarkable chest X-rays and does not say who reads the studies set aside.
Lunit publishes no business associate position for its products. Qure states a scope position: its cloud path receives only images stripped of identifiers. Neither publishes pricing.